in 2017, so much of the data supporting these recommendations remains largely indirect or of low quality. Similar to the last guideline, the major limitation remains the paucity of high-quality direct evidence regarding the added risk of infection from medication use at the time of THA or TKA; therefore, these recommendations continue to rely on indirect studies describing results in patients without rheumatic diseases or on assumptions or conclusions extrapolated from nonsurgical studies. An